Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 4/20 | 0.57 |
| ▸ | MDM4 | O15151 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 2/20 | 0.53 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29423514 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29386346 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL7423417 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13163967 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29361981 | 1.00 | CASP3 (0.57) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29511158 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL8350965 | 0.91 | CASP3 (0.52) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL13636676 | 0.91 | MDM4 (0.51) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL18358965 | 0.91 | CASP3 (0.55) | CASP3MDM4TP53MDM2KMT2A | |
| SCHEMBL29477062 | 0.90 | MDM4 (0.55) | CASP3MDM4TP53MDM2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 148 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3972649-B1 | MCL-1 INHIBITOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE | NOVARTIS AG (CH) | 2026-05-13 | — | — | EP | disclosed |
| US-20260078133-A1 | RAS INHIBITORS | Revolution Medicines, Inc. | 2026-03-19 | — | — | US | disclosed |
| EP-3604326-B1 | PEPTIDE COMPOUND AND METHOD FOR PRODUCING SAME, COMPOSITION FOR SCREENING USE, AND METHOD FOR SELECTING PEPTIDE COMPOUND | FUJIFILM CORP (JP) | 2026-01-07 | — | — | EP | disclosed |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2025-09-25 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | PEPTIDREAM INC (JP) | 2024-12-05 | — | — | US | disclosed |
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2024-11-14 | — | — | US | disclosed |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-08-27 | — | — | US | disclosed |
| WO-2023207710-A9 | ANTIBODY-DRUG CONJUGATE, PHARMACEUTICAL COMPOSITION THEREOF AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2024-07-25 | — | — | WO | disclosed |
| CN-118256591-A | Cyclic peptide compound having high membrane permeability and library comprising same | 中外制药株式会社 | 2024-06-28 | — | — | CN | disclosed |
| EP-0941233-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1999-09-15 | — | — | EP | disclosed |
| EP-0454651-B1 | Novel platelet-aggregation inhibitors | MONSANTO CO (US) | 1999-07-28 | — | — | EP | disclosed |
| US-5866684-A | Peptidyl inhibitors of viral proteases | HOFFMANN-LA ROCHE INC. (US) | 1999-02-02 | — | — | US | disclosed |
| WO-1998022496-A2 | ANTIVIRAL PEPTIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 1998-05-28 | — | — | WO | disclosed |
| EP-0352249-B1 | NOVEL PLATELET-AGGREGATION INHIBITORS | Monsanto Company (US) | 1993-09-08 | — | — | EP | disclosed |
| US-5091396-A | Guanidinoalkanoylaspartylpyridine derivatives; anticoagulants | MONSANTO CO. (US) | 1992-02-25 | — | — | US | disclosed |
| EP-0454651-A2 | Novel platelet-aggregation inhibitors | MONSANTO COMPANY (US) | 1991-10-30 | — | — | EP | disclosed |
| US-5037808-A | Indolyl platelet-aggregation inhibitors | MONSANTO CO. (US) | 1991-08-06 | — | — | US | disclosed |
| US-4992463-A | Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation | MONSANTO COMPANY (US) | 1991-02-12 | — | — | US | disclosed |
| US-4879313-A | ANTICOAGULANTS | MOSANTO COMPANY (US) | 1989-11-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260078133-A1 | RAS INHIBITORS | KRAS, NRAS, HRAS | CASP3 4305/4885MDM4 1445/4885TP53 24/4885 |
| US-20250296915-A1 | NOVEL AMINO ACID DERIVATIVES | DNPEP, BCAT1, ANPEP | CASP3 4173/4885MDM4 1740/4885TP53 1257/4885 |
| US-20240376044-A1 | METHOD FOR PREPARING AROMATIC AMINO ACID DERIVATIVE | DDC, AADAT, TYR | CASP3 4077/4885MDM4 381/4885TP53 1369/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CASP3 343/4885MDM4 3559/4885TP53 2654/4885 |
| US-20240400499-A1 | NOVEL AMINO ACID DERIVATIVES | BCAT1, BCAT2, PELP1 | CASP3 4451/4885MDM4 2155/4885TP53 3262/4885 |
| US-12071396-B2 | Method for preparing aromatic amino acid derivative | DDC, AADAT, TYR | CASP3 4077/4885MDM4 381/4885TP53 1369/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.